Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells
Journal Title
Cell Reports Medicine
Publication Type
epub ahead of print
Abstract
Immunocompromised hematology patients are vulnerable to severe COVID-19 and respond poorly to vaccination. Relative deficits in immunity are, however, unclear, especially after 3 vaccine doses. We evaluated immune responses in hematology patients across three COVID-19 vaccination doses. Seropositivity was low after a first dose of BNT162b2 and ChAdOx1 (∼26%), increased to 59%-75% after a second dose, and increased to 85% after a third dose. While prototypical antibody-secreting cells (ASCs) and T follicular helper (Tfh) cell responses were elicited in healthy participants, hematology patients showed prolonged ASCs and skewed Tfh2/17 responses. Importantly, vaccine-induced expansions of spike-specific and peptide-HLA tetramer-specific CD4(+)/CD8(+) T cells, together with their T cell receptor (TCR) repertoires, were robust in hematology patients, irrespective of B cell numbers, and comparable to healthy participants. Vaccinated patients with breakthrough infections developed higher antibody responses, while T cell responses were comparable to healthy groups. COVID-19 vaccination induces robust T cell immunity in hematology patients of varying diseases and treatments irrespective of B cell numbers and antibody response.
Publisher
Elsevier
Keywords
B cells; CD4(+) T cells; CD8(+) T cells; COVID-19 vaccines; SARS-CoV-2; T follicular helper cells; antibody-secreting cells; hematology; memory T cells; tetramer-specific
Research Division(s)
Blood Cells And Blood Cancer
PubMed ID
37030296
Open Access at Publisher's Site
https://doi.org/10.1016/j.xcrm.2023.101017
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-04-18 01:58:54
Last Modified: 2023-04-18 03:08:34
An error has occurred. This application may no longer respond until reloaded. Reload 🗙